-
公开(公告)号:US20230295297A1
公开(公告)日:2023-09-21
申请号:US18171291
申请日:2023-02-17
Applicant: Alector LLC
Inventor: Tina SCHWABE , Fracesca AVOGADRI-CONNORS , Helen LAM , Ilaria TASSI , Seung-Joo LEE , Arnon ROSENTHAL
CPC classification number: C07K16/2803 , A61P25/28 , A61K2039/505
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US20220315656A1
公开(公告)日:2022-10-06
申请号:US17740100
申请日:2022-05-09
Applicant: Alector LLC
Inventor: Kate MONROE , Helen LAM , Patricia CULP , Arnon ROSENTHAL
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-5 protein, e.g., human Siglec-5 or a mammalian Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US20220162309A1
公开(公告)日:2022-05-26
申请号:US17581471
申请日:2022-01-21
Applicant: Alector LLC
Inventor: Patricia CULP , Helen LAM , Arnon ROSENTHAL , Seung-Joo LEE , Nels P. NIELSON , Robert PEJCHAL
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US20210395361A1
公开(公告)日:2021-12-23
申请号:US17263534
申请日:2019-07-26
Applicant: Alector LLC
Inventor: Patricia CULP , Rashmi BANKOTI , Helen LAM , Arnon ROSENTHAL
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a Siglec-5 protein, e.g., human Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US20210139581A1
公开(公告)日:2021-05-13
申请号:US16869315
申请日:2020-05-07
Applicant: ALECTOR LLC
Inventor: Patricia CULP , Helen LAM , Arnon ROSENTHAL , Seung-Joo LEE , Nels P. NIELSON , Robert PEJCHAL
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US20190010230A1
公开(公告)日:2019-01-10
申请号:US16138761
申请日:2018-09-21
Applicant: Alector LLC
Inventor: Kate MONROE , Tina SCHWABE , Francesca AVOGADRI-CONNORS , Ilaria TASSI , Helen LAM , Arnon ROSENTHAL
Abstract: The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.
-
公开(公告)号:US20170240631A1
公开(公告)日:2017-08-24
申请号:US15502766
申请日:2015-08-08
Applicant: ALECTOR LLC
Inventor: Kate MONROE , Tina SCHWABE , Francesca AVOGADRI-CONNORS , IIaria TASSI , Helen LAM , Arnon ROSENTHAL
IPC: C07K16/28
CPC classification number: C07K16/2803 , A61K2039/505 , C07K16/28 , C07K16/283 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/75 , C07K2317/76 , C07K2317/92
Abstract: The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.
-
-
-
-
-
-